knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 01:35:43 - browse：5651

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： For Cytokinetics, FDA rejection of heart drug would help, not hinder

WSS

Leukemia patients are helped by Syndax's new type of therapy

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

FDA approves world's first CRISPR

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Wegovy trial has doctors encouraged over new possibilities

entertainment

knowledge

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Cancer drug shortages should be causing more outrage

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Heart attack and stroke risk calculators need revising

AI models in health care face new federal disclosure requirements

Virginia high school admissions case could be legal follow

Americans' trust in science, scientist continues decline: Report

The cancer drug shortage isn’t new — and neither are the solutions

SCOTUS to consider access to abortion pill mifepristone

Wikipedia

Maui's cultural, historic landmarks damaged in the devastating wildfires

Patients' immediate access to test results puts radiologists in a bind

Anavex keeps shifting the goalposts in its clinical trials

Anavex keeps shifting the goalposts in its clinical trials

Pharma patents targeted by Biden in move to slash drug prices

For Cytokinetics, FDA rejection of heart drug would help, not hinder

hotspot

focus

hotspot

hotspot